Imara-Logo-Color-RGB.jpg
Imara Announces Recipients of the Second Annual Real Impact Grants Program to Support People Affected by Rare Genetic Blood Disorders
June 17, 2021 07:00 ET | Imara, Inc.
BOSTON, June 17, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Presents Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 11, 2021 03:00 ET | Imara, Inc.
Final data from 93-patient Phase 2a clinical trial show lower annualized rate of vaso-occlusive crises (VOCs) and longer time to first VOC on IMR-687 Interim open-label extension clinical trial...
Imara-Logo-Color-RGB.jpg
Imara to Present Clinical Data on IMR-687 in Sickle Cell Disease at the European Hematology Association (EHA) Annual Congress
June 04, 2021 07:00 ET | Imara, Inc.
Oral presentation provides final results from 93-patient Phase 2a trial and additional interim data from open label extension trial Imara to host conference call and live webcast on June 11, 2021 at...
Imara-Logo-Color-RGB.jpg
Imara Reports First Quarter 2021 Financial Results and Business Highlights
May 11, 2021 07:00 ET | Imara, Inc.
On-track to report interim analyses for both Ardent sickle cell disease and Forte beta-thalassemia Phase 2b clinical trials in the second half of 2021 Completed enrollment in the...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of First Quarter 2021 Financial Results and Business Highlights
May 04, 2021 07:00 ET | Imara, Inc.
BOSTON, May 04, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Opens Applications for the Second-Annual ‘Real Impact’ Community Support Program to Address Unmet Needs Affecting People with Rare Genetic Blood Disorders
March 29, 2021 07:00 ET | Imara, Inc.
BOSTON, March 29, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara Announces Opening of Higher Dose Arms in Global Phase 2b Clinical Trials of IMR-687 for Sickle Cell Disease and Beta-Thalassemia
March 17, 2021 07:00 ET | Imara, Inc.
Independent Data Monitoring Committees endorse opening higher dose IMR-687 treatment arms in ongoing Ardent and Forte Phase 2b clinical trials after review of safety and tolerability data at lower...
Imara-Logo-Color-RGB.jpg
Imara Reports Full Year 2020 Financial Results and Business Highlights
March 05, 2021 07:00 ET | Imara, Inc.
Significant progress advancing IMR-687 as an oral, once-a-day potentially disease modifying treatment for sickle cell disease and beta-thalassemia Reports new Phase 2a open label extension clinical...
Imara-Logo-Color-RGB.jpg
Imara to Webcast Conference Call of Full Year 2020 Financial Results and Business Highlights
February 26, 2021 21:30 ET | Imara, Inc.
BOSTON, Feb. 26, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...
Imara-Logo-Color-RGB.jpg
Imara to Present at SVB Leerink 10th Annual Global Healthcare Conference
February 19, 2021 07:00 ET | Imara, Inc.
BOSTON, Feb. 19, 2021 (GLOBE NEWSWIRE) -- Imara Inc. (Nasdaq: IMRA), a clinical-stage biopharmaceutical company dedicated to developing and commercializing novel therapeutics to treat patients...